Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
The final week of August could be highly volatile as markets fret over the economy and the latest developments in trade wars.Market Insiderread more
Federal Reserve Vice Chair Richard Clarida said Friday that the global economy has deteriorated in the past month.Marketsread more
The latest escalation in the trade war ups the odds the economy will fall into recession and that the Fed will aggressively cut rates.Market Insiderread more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
"We don't need China and, frankly, would be far better off without them," Trump tweeted.Politicsread more
Recent trade friction between the two Asian powerhouses has morphed into a dispute with political implications that go far beyond the region.Asia Politicsread more
"My only question is, who is our bigger enemy, Jay Powell or Chairman Xi?" Trump wrote amid a series of tweets that rattled markets Friday.Politicsread more
"I would love this to be clarified. We come to a deal on trade, boy, this market is up 10 to 15%, but without it's going to be worrisome," Jeremy Siegel says.Marketsread more
Tesla solar energy systems reportedly ignited at an Amazon warehouse in Redlands, California last June, and the Seattle e-commerce titan confirmed that it has no further plans...Technologyread more
BEIJING, May 16 (Reuters) - British livestock genetics firm Genus agreed on Thursday to license its know-how on virus-resistant pigs to state-owned Beijing Capital Agribusiness Co Ltd (BCA), which will seek regulatory approval for the pigs in the world's top pork market.
Under the deal, BCA will set up a firm called Beijing Shou Nong Future Bio-Tech Co. Ltd that will fund the development of the market and seek regulatory approval, expected to take several years, for the raising of pigs resistant to the Porcine Reproductive and Respiratory Syndrome (PRRS) virus.
Genus shares surged more than 15% after the announcement and were on course for their best day in 17 years.
Genus has a global patent for commercialisation of pigs genetically edited to be resistant PRRS, a virus that causes billion-dollar losses for the global pig industry each year.
Under the deal, Genus will receive upfront and milestone cash payments of $20 million subject to certain conditions being fulfilled.
It will later receive between $120 million and $160 million for the creation with BCA of a joint venture, including Genus's existing pig genetics operations in China, after regulatory approval of PRRS-resistant pigs has been obtained in China.
Genus will also get royalties from the joint venture on sales in China of PRRS-resistant pigs.
PRRS, also known as 'blue-ear disease', often kills piglets and in some cases, also sows. It costs the U.S. and European hog industry about $2.5 billion each year in lost revenue, according to one estimate by the University of Edinburgh.
($1 = 0.7784 pounds)
(Reporting by Dominique Patton; editing by Kenneth Maxwell and Christian Schmollinger)